Clinical Trials Browser

Phase 2 × Lymphoma × entinostat × Clear all

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Phase 2 Active not recruiting

Lymphoma, Recurrence